Alkermes Plc. (ALKS)

followers · Follow

Sector:

HEALTH CARE

Industry:

PHARMACEUTICALS

SIC:

PHARMACEUTICAL PREPARATIONS

CEO:

Richard F. Pops

Employees:

2280

CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, L2, 00000

00-353-1-772-8000

alkermes.com

Stock Split History
Date	Ratio
2000-05-15	2:1

Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Alkermes Plc. YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available